Latest News

Indian Shares May Extend Gains

(RTTNews) – Indian stocks are likely to open higher, tracking positive global cues and reacting to the data on industrial production.

Asian markets are mostly higher amid optimism about the trade talks between the U.S. and China resulting in a long term deal before the end of the 90-day truce period.

Markets in U.S. and Europe closed on a high note overnight on optimism about a U.S.-China deal.

However, after recent strong gains, the Indian market may face some resistance at higher levels.

According to a report released by the government after trading hours on Wednesday, India’s industrial production surged 8.1% in October, the fastest pace in eleven months, compared to 4.5% growth recorded in September 2018. The production growth for September has been retained unchanged from 4.5% increase reported provisionally.

Meanwhile, CPI inflation dipped to a 17-month low of 2.33% in November (new base 2012=100), as compared to 3.38% in October. The core CPI inflation eased to 5.71% in November, compared to 6.2% a month earlier.

Strides Pharma Science announced that is subsidiary Strides Pharma Global, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food Drug Administration. The Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.

Lupin announced that an European court has upheld a decision to impose a fine of over Rs 325 crore on the company by European Commission in a litigation over blood pressure lowering drug Perindopil.

Realty firm DLF announced that its Chief Financial Officer Saurabh Chawla has resigned from the company.

On Wednesday, the Sensex ended up 629.06 points, or 1.79%, at 35,779.07, while the Nifty50 closed up by 188.45 points, or 1.79%, at 10,737.60.

LG to Unveil Capsule-Based Craft Beer System at CES 2019

Tuesday December 11 th 2018

Automated Process and Exclusive Technologies
Deliver Total DIY Solution for Beer Enthusiasts

TORONTO, Dec. 10, 2018 /CNW/ – LG Electronics (LG) will debut a capsule-based craft beer making machine, LG HomeBrew, at CES 2019. A winner of a 2019 CES Innovation Award, the state-of-the-art device makes the brewing process incredibly easy thanks to its single-use capsules, optimized fermentation algorithm and convenient self-cleaning feature, the ideal product for anyone seeking the satisfaction of creating their own cold, tasty beer.

LG’s unique capsule-based system brings revolutionary simplicity to the art of brewing with one-touch activation. With a set of single-use capsules – which contain malt, yeast, hop oil and flavoring – and the press of a button, users can relax as LG HomeBrew automates the whole procedure from fermentation, carbonation and aging to serving and cleaning. A free companion app (for Android and iOS devices) lets users check HomeBrew’s status at any time, anywhere.

HomeBrew not only offers an incredibly simple way to make craft beer, it also enhances the quality of beer it makes. An optimized fermentation algorithm intelligently controls the fermenting process with precise temperature and pressure control for guaranteed brewing success. The clever capsule system also removes all the cleaning-related frustrations associated with traditional home-brewing methods. It automatically sanitizes using nothing more than hot water, ensuring everything is hygienically clean for the next batch.

Designed with discerning beer lovers in mind, HomeBrew allows for the in-home production of various popular styles insuring excellent results with every batch. Five distinctive, richly-flavored beers are sure to impress: hoppy American IPA, golden American Pale Ale, full-bodied English Stout, zesty Belgian-style Witbier and dry Czech Pilsner. It can produce up to five litres of premium quality beer in approximately two weeks depending on the beer type.

“LG HomeBrew is the culmination of years of home appliance and water purification technologies that we have developed over the decades,” said Song Dae-hyun, president of LG Electronics Home Appliance Air Solution Company. “Homebrewing has grown at an explosive pace but there are still many beer lovers who haven’t taken the jump because of the barrier to entry and these are the consumers we think will be attracted to LG HomeBrew.”

Visitors to CES 2019 from January 8-11 will be able to experience LG’s revolutionary HomeBrew at booth #11100 in the Las Vegas Convention Center.

About LG Electronics Home Appliance Air Solutions

LG Electronics is a global leader in home appliances, air conditioning and air quality systems. The company is creating total solutions for the home with its industry leading core technologies. LG is committed to making life better for consumers around the world by providing thoughtfully designed products, including refrigerators, washing machines, dishwashers, cooking appliances, vacuum cleaners, built-in appliances, air conditioners, air purifiers and dehumidifiers. Collectively, these products deliver enhanced convenience, superb performance, great savings and compelling health benefits. For more information, please visit  

About LG Electronics Canada Inc.

The LG brand was established in 1995. The company is a global leader in electronics, information and communications products, with more than 117 operations around the world, and annual worldwide revenues of more than US $49 billion. LG Electronics Canada Inc. is comprised of five business units – Mobile Communications, Home Appliance, Home Entertainment, Business Solutions and Commercial Air Conditioning. The company has offices in Toronto and Vancouver. LG Electronics Canada Inc. is focused on delivering award-winning products known for blending style and technology. These innovative products include cell phones, flat screen TVs, laptop computers and home appliances. For more information please visit

SOURCE LG Electronics, Inc.

A top YouTuber did a ‘blind’ test to find the very best smartphone camera, and the iPhone lost in the first round (AAPL, GOOG, GOOGL)

Tuesday December 4 th 2018

Marques Brownlee, iPhone vs BlackberryMKBHD/YouTube

  • On paper, and in technical comparisons, the iPhone XS ranks among the world’s best smartphones when it comes to photography.
  • But in a blind test conducted by popular YouTube tech vlogger Marques Brownlee, the iPhone XS flunked out in the first round.
  • Crazier still, it lost against a BlackBerry smartphone. Google’s Pixels, renowned for their camera quality, fared just as poorly.

One of the main reasons that people buy the iPhone is for its ability to take high-quality, detailed photos. And it certainly does that!

But based on the results of a new video from YouTube vlogger Marques “MKBHD” Brownlee, it seems like another factor may be far more important: Brightness.

In a massive blind photo test that Brownlee conducted over social media, he pit 16 different smartphones against each other. Both the iPhone X and the iPhone XS flunked out in the first round to less capable smartphones — Xiaomi’s Pocophone F1 and TCL’s BlackBerry Key2, respectively.

That’s right: Apple’s flagship iPhone from this year and last failed out in the first round, against phones that are barely considered competition normally.

Google’s flagship Pixel line did just as poorly, albeit against more technically competitive devices.

Marques Brownlee (Huwaei Mate 20 Pro vs Pocophone)MKBHD/YouTube

His test was simple: Put two photos of the same subject next to each other and have his millions of social media followers vote on which looked better to them. 

It’s hardly a scientific poll, but that’s not the point — what you see is what matters.

Most people are looking at photos on smartphone screens, through social media apps that compress images. They’re using apps on their smartphone to edit images before sharing. They’re trying to see faces clearly. Does the image “pop?” Is it bright? 

That kind of interaction with photos leads to a different type of preference.

“The most important thing to people, when viewing these photos straight out of camera, was just exposure — brightness, basically,” Brownlee says in the video. “Nine times out of ten, the brighter, more saturated, more punchy-contrasty photo, won. Every single round — it’s pretty consistent.” 

Marques Brownlee (MKBHD)Marques Brownlee/YouTube

It says a lot about what actually matters in smartphone cameras, and what may matter to you.

Are you taking a lot of extremely detailed photos with your smartphone? If the answer is no, then maybe you can wait a little longer next time before upgrading your smartphone — or maybe it’s finally time to start considering those mid-range, less expensive smartphones.

If nothing else, the video is a fascinating look into modern smartphone camera options — see it for yourself right here:

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

Sunday December 2 nd 2018

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster IIâ€� at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The poster, titled “Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Lymphoid Malignancy Patients with Prior BTKi Therapy,â€� Abstract No. 3141, is available at

“To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,� said Dayton Misfeldt, Sunesis interim Chief Executive Officer. “We believe vecabrutinib has significant potential to be an important new treatment for ibrutinib-resistant B-cell malignancy patients, and its additional activity as an ITK inhibitor suggests further directions for clinical investigation. We look forward to continuing the dose escalation, as we believe that the target dose level is likely to be between 100 mg and 300 mg BID. We are excited to be working with such thoughtful and diligent investigators at eight premier sites across the U.S., and we thank our investigators for their continued support.�

Data reported today were available from 11 of 13 treated patients. These included 7 with relapsed/refractory CLL, two with mantle cell lymphoma (MCL), and two with Waldenstrom macroglobulinemia (WM). Patients had received an average of 5 lines of prior therapy, and all had progressed on prior covalent BTK inhibitor treatment. Four of the 7 CLL patients had BTK C481 mutations. Currently, 4 patients are on study: one in Cycle 2, one in Cycle 3, and two new subjects who are in Cycle 1 and are anticipated to complete the 50 mg cohort.

The poster builds vecabrutinib’s profile in three key areas:

  • Safety: data on treatment-emergent adverse events (TEAEs) were available for 10 patients. The most common TEAEs of any grade were anemia (70%) and neutropenia and night sweats (50% each). Grade 3 drug-related AEs were anemia, neutropenia, leukocytosis, and ALT increase (10% each). In the second cohort, one patient experienced a dose-limiting toxicity of an inadequate number of Cycle 1 doses administered due to a drug-related grade 3 ALT elevation, resulting in expansion of the cohort to 6 patients.
  • Pharmacokinetics: the pharmacokinetic profile of the 50mg dose is approximately dose proportional to the 25 mg dose. The next dose levels are expected to produce plasma concentrations associated with consistently high inhibition of BTK.
  • Pharmacodynamics: vecabrutinib inhibition of BTK phosphorylation was rapid and sustained in the 5 patients who had adequate baseline signal for analysis. Decreases in serum concentrations of key cytokines associated with B-cell malignancies, CCL2, CCL3, and CCL4, were also observed in 7 patients, consistent with inhibition of BTK signaling.

Webcast Information

The data will be further discussed as part of an analyst and investor event being held in San Diego today, December 2, at 8:00 p.m. PT, with the slide webcast commencing at 8:30 p.m. PT. The event is intended for institutional investors and sell-side analysts only. Please contact for more information. The live webcast of the event, with slides, will be available to all on the Investors section of the Sunesis website at and will be archived for 90 days.

About Vecabrutinib

Vecabrutinib (SNS-062) is a selective, oral, reversible, non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). BTK is a validated target for the treatment of B-cell malignancies driven by B-cell receptor signaling. Vecabrutinib retains its activity in the presence of a BTK C481S mutation, the most common mutation seen in ibrutinib-resistant CLL patients. In preclinical studies, vecabrutinib demonstrated potent activity in both wild-type and C481S-mutant BTK. Vecabrutinib has also been shown to inhibit a select number of other kinases including IL2-inducible T-cell kinase (ITK), which may improve T cell function. In a Phase 1a randomized, double-blind, placebo-controlled single ascending dose study in healthy volunteers, vecabrutinib demonstrated improved pharmacokinetics over ibrutinib, and sustained inhibition of BTK. Vecabrutinib is now being investigated in a Phase 1b/2 study in patients with relapsed CLL and other B-cell malignancies.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis plans to submit an IND for SNS-510 in 2019. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.

For additional information on Sunesis, please visit

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including statements related to the continued development of vecabrutinib (SNS-062), including the timing and preliminary results of Phase 1b/2 trial of vecabrutinib and the therapeutic potential of vecabrutinib, further development and potential of its kinase inhibitor pipeline, and planned development of SNS-510 and TAK-580. Words such as “believe,â€� “expect,â€� “future,â€� “look forward,â€� “potential,â€� “will,â€� and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk related to the timing or conduct of Sunesis’ clinical trials, including the vecabrutinib Phase 1b/2 trial, the risk that Sunesis’ clinical or preclinical studies for vecabrutinib, SNS-510 or other product candidate may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, risks related to the timing or conduct of Sunesis’ clinical trials, that Sunesis’ development activities for vecabrutinib or SNS-510 could be otherwise halted or significantly delayed for various reasons, that Sunesis may not be able to receive regulatory approval of vecabrutinib, or SNS-510 in the U.S. or Europe, and risks related to Sunesis’ ability to raise the capital that it believes to be accessible and is required to fully finance the development and commercialization of vecabrutinib, SNS-510 and other product candidates. These and other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and Sunesis’ other filings with the Securities and Exchange Commission.  Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein reflect any change in Sunesis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.